CDC warns of rising spread of babesiosis through blood transfusions http://t.co/lTwKaKL
266 days ago
Very disappointing study, scary how decisions based on so few #s: Cancer trial participation less than 1% http://t.co/RhY7Mkg via @addthis
277 days ago
You may have already seen blog @ Digital Pathology Blog but check out the Pathology Visions Conference-should be great! http://t.co/TVW0M7P
279 days ago
WCLC 2011 Oral Presentations: (More) Genomics http://t.co/xIOaw9j
280 days ago
New therapeutic approaches for small cell lung cancer
Posted Dec 13 2009 12:00am
I am currently working on a project with our lung cancer research group at Rush University Medical Center in Chicago in which we are looking at expression of the BCL-2 family protein, MCL-1. MCL-1 is interesting because it can either be anti- or pro-apoptotic depending on alternative splicing. So I was interested in this nice review article that explores the role of novel targeted agents in SCLC. This article specifically discusses agents targeting the bcl-2 protein family. The prognosis for SCLC remains pretty dismal but there is a lot of interest in this malignancy because of the better understanding of pathways involved in SCLC and the development of "targeted" therapies.
Hurwitz J, McCoy F, Scullin P, Fennell D. New advances in the second-line treatment of small cell lung cancer. Oncologist. 2009;14(10):986-994.
I am currently working on a project with our lung cancer research group at Rush University Medical Center in Chicago in which we are looking at expression of the BCL-2 family protein, MCL-1. MCL-1 is interesting because it can either be anti- or pro-apoptotic depending on alternative splicing. So I was interested in this nice review article that explores the role of novel targeted agents in SCLC. This article specifically discusses agents targeting the bcl-2 protein family. The prognosis for SCLC remains pretty dismal but there is a lot of interest in this malignancy because of the better understanding of pathways involved in SCLC and the development of "targeted" therapies.
Hurwitz J, McCoy F, Scullin P, Fennell D. New advances in the second-line treatment of small cell lung cancer. Oncologist. 2009;14(10):986-994.